A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
Latest Information Update: 15 Sep 2026
At a glance
- Drugs SHR 1139 (Primary)
- Indications Pyoderma gangrenosum
- Focus Therapeutic Use
Most Recent Events
- 09 Sep 2026 Protocol has been amended(Time frame of primary end point).
- 09 Sep 2026 Status changed from not yet recruiting to recruiting.
- 22 Jan 2026 New trial record